These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 20413364)

  • 61. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
    Charlton-Menys V; Betteridge DJ; Colhoun H; Fuller J; France M; Hitman GA; Livingstone SJ; Neil HA; Newman CB; Szarek M; DeMicco DA; Durrington PN
    Diabetologia; 2009 Feb; 52(2):218-25. PubMed ID: 18972097
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
    J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
    Bone HG; Kiel DP; Lindsay RS; Lewiecki EM; Bolognese MA; Leary ET; Lowe W; McClung MR
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4671-7. PubMed ID: 17726081
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.
    Giral P; Bruckert E; Jacob N; Chapman MJ; Foglietti MJ; Turpin G
    Atherosclerosis; 2001 Feb; 154(2):421-7. PubMed ID: 11166775
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy.
    Puri R; Nissen SE; Shao M; Uno K; Kataoka Y; Kapadia SR; Tuzcu EM; Nicholls SJ
    Am J Cardiol; 2014 Nov; 114(10):1465-72. PubMed ID: 25282317
    [TBL] [Abstract][Full Text] [Related]  

  • 67. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
    Jones PH; Goldberg AC; Knapp HR; Kelly MT; Setze CM; Stolzenbach JC; Sleep DJ
    Am Heart J; 2010 Oct; 160(4):759-66. PubMed ID: 20934572
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound.
    Yamada K; Yoshimura S; Kawasaki M; Enomoto Y; Asano T; Minatoguchi S; Iwama T
    Cerebrovasc Dis; 2009; 28(4):417-24. PubMed ID: 19707015
    [TBL] [Abstract][Full Text] [Related]  

  • 70. MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course.
    Zhao XQ; Dong L; Hatsukami T; Phan BA; Chu B; Moore A; Lane T; Neradilek MB; Polissar N; Monick D; Lee C; Underhill H; Yuan C
    JACC Cardiovasc Imaging; 2011 Sep; 4(9):977-86. PubMed ID: 21920335
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.
    Komukai K; Kubo T; Kitabata H; Matsuo Y; Ozaki Y; Takarada S; Okumoto Y; Shiono Y; Orii M; Shimamura K; Ueno S; Yamano T; Tanimoto T; Ino Y; Yamaguchi T; Kumiko H; Tanaka A; Imanishi T; Akagi H; Akasaka T
    J Am Coll Cardiol; 2014 Dec; 64(21):2207-17. PubMed ID: 25456755
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of intensive atorvastatin therapy on coronary atherosclerosis progression, composition, arterial remodeling, and microvascular function.
    Eshtehardi P; McDaniel MC; Dhawan SS; Binongo JN; Krishnan SK; Golub L; Corban MT; Raggi P; Quyyumi AA; Samady H
    J Invasive Cardiol; 2012 Oct; 24(10):522-9. PubMed ID: 23043036
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
    Gao F; Ballantyne C; Ma L; Virani SS; Keinan A; Brautbar A
    Atherosclerosis; 2014 Jun; 234(2):249-53. PubMed ID: 24704626
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.
    Forst T; Wilhelm B; Pfützner A; Fuchs W; Lehmann U; Schaper F; Weber M; Müller J; Konrad T; Hanefeld M
    Diab Vasc Dis Res; 2008 Nov; 5(4):298-303. PubMed ID: 18958840
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
    Cashin-Hemphill L; Kramsch DM; Azen SP; DeMets D; DeBoer LW; Hwang I; Vailas L; Hirsch LJ; Mack WJ; DeBoer L
    Online J Curr Clin Trials; 1992 Oct; Doc No 26():[9897 words; 83 paragraphs]. PubMed ID: 1343613
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.
    Chan DC; Watts GF; Ooi EM; Rye KA; Ji J; Johnson AG; Barrett PH
    Diabetes Care; 2009 Nov; 32(11):2111-3. PubMed ID: 19651918
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Implications of the atorvastatin versus revascularization treatment (AVERT) study for the clinician.
    Eisenberg D
    Curr Cardiol Rep; 2000 Sep; 2(5):433-8. PubMed ID: 10980911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.